Prosecution Insights
Last updated: November 20, 2026

Matthew P Coughlin, USPTO Patent Examiner

Listed by the USPTO as COUGHLIN, MATTHEW P

Tech Center 1600 • Art Units: 1626 1691

This examiner grants 71% of resolved cases

Analysis

COUGHLIN, MATTHEW P examines in Tech Center 1600 and Art Unit 1626. The profile covers 1,015 resolved cases and reports a 71.2% allowance rate. The median time to allowance is 892 days, providing a substantial record for evaluating expected outcome and examination duration.

The interview lift is 12.6%. The listed companies are Bristol-Myers Squibb Company, University of Florida Research Foundation Inc., and Hoffmann-La Roche Inc. The listed firms are BALLARD SPAHR LLP, Sterne, Kessler, Goldstein & Fox P.L.L.C., and BakerHostetler. These organizations identify recorded prosecution participants and may provide useful context for related matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

71.2%
Allow Rate
+11.2% vs TC avg
1,069
Total Applications
+12.6%
Interview Lift
892
Avg Prosecution Days
Based on 1015 resolved cases, 2023–2026

Rejection Statute Breakdown

2.8%
§101 Eligibility
19.0%
§102 Novelty
24.2%
§103 Obviousness
32.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18782144 METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS Non-Final OA University of Florida Research Foundation, Inc.
17976651 NOVEL IMIDAZOPYRAZINE DERIVATIVES Non-Final OA Hoffmann-La Roche Inc.
18909652 NLRP3 INFLAMMASOME INHIBITORS Non-Final OA Novartis AG
18363004 ANTIMICROBIAL COMPOSITION COMPRISING A DIOCTYLDIMETHYLAMMONIUM COMPOUND Non-Final OA The Procter & Gamble Company
16772768 SUBSTITUTED AROMATIC AMINES FOR USE IN ORGANIC ELECTROLUMINESCENT DEVICES Non-Final OA Merck Patent GmbH
18828945 GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS Non-Final OA Eli Lilly and Company
18375697 COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS Final Rejection OHIO STATE INNOVATION FOUNDATION
18526795 USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY Non-Final OA Jazz Pharmaceuticals Research UK Limited
18015746 MONOTERPENOID AND PHENYLPROPANOID CARBONATE ESTERS AND METHODS OF THEIR MAKING AND USE AS REPELLENTS Non-Final OA IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
18686802 BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
18123018 Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds Non-Final OA Purdue Research Foundation
18758924 Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy Final Rejection Rutgers, The State University of New Jersey
18963289 PHARMACEUTICAL COMPOSITION CONTAINING FRAXETIN FOR PREVENTION OR TREATMENT OF ENDOMETRIOSIS Non-Final OA SEOUL NATIONAL UNIVERSITY HOSPITAL
18555112 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER Final Rejection Yale University
18259606 Metal Complexes and Methods for the Same Non-Final OA Colgate-Palmolive Company
18873229 TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS Non-Final OA Bristol-Myers Squibb Company
18331831 KRAS INHIBITORS Non-Final OA Bristol-Myers Squibb Company
18036095 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES Final Rejection Icahn School of Medicine at Mount Sinai
18325264 PROCESS FOR PRODUCING FURFURAL FROM BIOMASS Final Rejection UOP LLC
18274293 COMPOSITIONS AND METHODS FOR INHIBITING YAP Non-Final OA The United States Government as represented by the Department of Veterans Affairs
18858952 SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR Non-Final OA ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Matthew P Coughlin's allowance rate?

71.2% of resolved applications examined by Matthew P Coughlin were allowed (1,015 resolved cases), compared with 54.6% across Art Unit 1626 over the last five years.

Does an interview help with examiner Matthew P Coughlin?

This examiner's interview lift is +12.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Matthew P Coughlin take to allow a patent?

Applications allowed by Matthew P Coughlin took 892 days on average from filing to allowance.

Which art unit does examiner Matthew P Coughlin work in?

Matthew P Coughlin examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month